Adlai Nortye (ANL) Total Current Liabilities (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Total Current Liabilities of $41.6 million for Q4 2025, down 8.23% year-over-year from $45.4 million in Q4 2024, and down 34.82% quarter-over-quarter from $63.9 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Total Current Liabilities (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Total Current Liabilities for 4 consecutive years, with $41.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 8.23% year-over-year to $41.6 million; the TTM figure through Dec 2025 stood at $41.6 million (down 8.23% YoY), while the FY2025 annual figure was $41.6 million, down 8.23% from the prior year.
- Total Current Liabilities fell to $41.6 million in Q4 2025 per ANL's latest filing, from $63.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $312.7 million in Q4 2022 and bottomed at $41.6 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $94.6 million across 4 years, with a median of $52.0 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 84.11% — and 2025, when it advanced 17.59%.
- Adlai Nortye's Total Current Liabilities stood at $312.7 million in 2022, then slumped by 84.11% to $49.7 million in 2023, then retreated by 8.68% to $45.4 million in 2024, then declined by 8.23% to $41.6 million in 2025.
- Business Quant data shows ANL's Total Current Liabilities at $41.6 million in Q4 2025, $63.9 million in Q2 2025, and $45.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 25.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.22 Mn |
| Dec 31, 2025 | 41.63 Mn |
| Jun 30, 2025 | 63.87 Mn |
| Dec 31, 2024 | 45.36 Mn |
| Jun 30, 2024 | 54.31 Mn |
| Dec 31, 2023 | 49.67 Mn |
| Dec 31, 2022 | 312.65 Mn |